Location History:
- Chesapeake, VA (US) (2009 - 2013)
- Virginia Beach, VA (US) (2014 - 2015)
Company Filing History:
Years Active: 2009-2015
Title: Innovations of Richard A. Britten in Hadron Treatment Planning
Introduction
Richard A. Britten is a notable inventor based in Virginia Beach, VA, with a significant contribution to the field of medical treatment planning. He holds a total of 8 patents, showcasing his innovative approach to enhancing treatment methods for patients with medical conditions.
Latest Patents
One of his latest patents focuses on hadron treatment planning with adequate biological weighting. This patent outlines treatment planning methods that determine the variability of relative biological effectiveness (RBE) along a beam line. It calculates the intensity of hadron beams, such as proton or carbon ion beams, necessary to achieve a desired biological dose at the treatment site. Typically, three or four RBE values are calculated at various spatially-dispersed intervals along the beam line. In one embodiment, two RBE values are determined for the spread-out Bragg peak (SOBP) region of the treatment site, one for the proximal section and another for the declining distal section. Additionally, a third RBE value may be calculated for the distal edge region of the SOBP, with a fourth value potentially calculated for a pre-SOBP region.
Career Highlights
Richard A. Britten is affiliated with Hampton University, where he continues to contribute to advancements in medical technology and treatment planning. His work has been instrumental in improving the precision and effectiveness of hadron therapy.
Collaborations
He collaborates with esteemed colleagues such as Vahagn R. Nazaryan and Cynthia Keppel, further enhancing the research and development efforts in his field.
Conclusion
Richard A. Britten's innovative contributions to hadron treatment planning exemplify the intersection of technology and medicine. His patents reflect a commitment to improving patient care through advanced treatment methodologies.